adjuvant chemotherapy for elderly women with breast cancer ... · october 2009. 2. 3 comorbidities...
TRANSCRIPT
![Page 1: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/1.jpg)
11
Adjuvant Chemotherapy for Adjuvant Chemotherapy for Elderly Women with Breast Cancer: Elderly Women with Breast Cancer:
Immediate Benefit and LongImmediate Benefit and Long--Term RiskTerm Risk
Matti S. Aapro, M.D.Matti S. Aapro, M.D.IMO Clinique de GenolierIMO Clinique de Genolier
SwitzerlandSwitzerland
SIOGBerlin
October 2009
![Page 2: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/2.jpg)
22
![Page 3: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/3.jpg)
33
COMORBIDITIES and concomittant treatment
modulate strategiesfor non MBC
BACKGROUND MESSAGE
![Page 4: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/4.jpg)
4
Life expectancy in senior adults: a large variability reflecting health status variability
18
1
4.35.8
7.9
10.8
14.2
2.33.2
4.7
6.7
12.4
9.3
1.52.23.3
6.74.9
0
5
10
15
20
25
70 years 75 years 80 years 85 years 90 years 95 years
Life
exp
ecta
ncy,
yea
rs
Top 25th percentile (FIT seniors)
Lowest 25th percentile (FRAIL seniors)
50th percentile (MEDIAN life expectancy)
Walter LC et al. JAMA 2001, 285, 2750-2756
Socioeconomicconditions
Pharmacy
Nutrition
Geriatric syndromes
Function
Emotional conditions
Comorbidity
Cognition
Domains
Health statusgroups
![Page 5: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/5.jpg)
55
![Page 6: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/6.jpg)
66
BUT COMORBIDITIESshould not be a reason to forget
clinical data andtumour biology
PROGNOSIS AND PREDICTION IN BREAST CANCER10th - 11th October 2008Principality of Monaco
![Page 7: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/7.jpg)
77
![Page 8: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/8.jpg)
88
Presents at a more advanced stagePresents at a more advanced stage
BUTBUTlower rates of lower rates of tumourtumour cell proliferation,cell proliferation,
a lower expression HER2a lower expression HER2a higher content of ER and a higher content of ER and PgRPgRa higher frequency of a higher frequency of diploidydiploidya lower frequency of p53 accumulationa lower frequency of p53 accumulation
AND!AND!20%to30% of older patients 20%to30% of older patients
poor/negative ER and poor/negative ER and PgRPgR expressionexpression
ELDERLY AND BREAST CANCERELDERLY AND BREAST CANCER
![Page 9: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/9.jpg)
99
UNDERTREATMENTUNDERTREATMENT
• 407 women > 80 years old
• 50% undertreated– No surgery or tumorectomy without radiation
• Reasons– Refusal ( patients ) : 14%– Physician or family decided…
• 5 year survival– « State of the art » : 90%– lesser therapy : 46%
Bouchardy, JCO 2003
![Page 10: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/10.jpg)
10
WILL an « ELDERLY » ACCEPT CHEMOTHERAPY?
• 320 outpatients ( France / USA ) aged 70 years to 95 years (29% aged 80 years and older)
• With and without cancer• Interviewed via anonymous questionnaires
• French noncancer patients (34%) were less willing to accept the strong chemotherapy than French cancer patients (77.8%), American noncancer patients (73.8%), and American cancer patients (70.5%) (P <.001 for each pair).
• This was also true for the moderate chemotherapy (67.9% v 100%, 95.2%, and 88.5%, respectively; P <.001).
Extermann M, Albrand G, Chen H, et al Are older French patients as willing as older American patients to undertake chemotherapy?J Clin Oncol. 2003 ;21:3214-9
![Page 11: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/11.jpg)
11
Courtesy of
A. Benavides
Which schedule ?
Any benefit ?
... in the elderly
![Page 12: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/12.jpg)
12
Which adj regimens for BrCa in the elderly
CMF 1,8 (6 cycles)CMF 1,8 (6 cycles)
CMF 1,8 (3 cycles) CMF 1,8 (3 cycles) **AA--based regimen (based regimen (4 cycles4 cycles))AA--based regimen (6based regimen (6 cyclescycles))3 weekly CMF 3 weekly CMF Personalized regimensPersonalized regimens
Score : 0= 0%; 10= 100% Score : 0= 0%; 10= 100% investigatorsinvestigators
RegimenRegimen
00 11 22 33 44 55 66 77 88 99 1010
ScoreScore
«« The BIG The BIG surveysurvey »» Biganzoli et al. Ann Biganzoli et al. Ann OncolOncol 20042004
*IBCSG trial VII: TAM vs CMF x 3 TAM (grade 3 tox in 65+)(Anthra: FASG-08; ICCG) Crivellari et al. JCO 2002
![Page 13: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/13.jpg)
13
Patients aged65 years and older
derive similar proportional improvement inrelapse-free and overall survival
as younger patients, but with a higher
rate of treatment-related mortality.
Muss HB, Woolf S, Berry D, et al: Adjuvantchemotherapy in older and youngerwomen with lymph node-positive breastcancer. JAMA 293: 1073-1081, 2005
![Page 14: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/14.jpg)
14
Further evidence for Adj chemoin elderly patients
SEER database
Adjuvant chemotherapy : 15% relative reduction in mortality among women aged 66 and over with hormone receptor-negative breast cancer (adjusted hazard ratio 0.85, 95% CI 0.77-0.95)
Elkin EG, Hurria A, Mitra N et al. J Clin Oncol 2006;24:2757-2764
![Page 15: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/15.jpg)
15
Late complications of adjuvant chemotherapy
• Clinically significant congestive heart failure develops in 0.5 to 1.0 percent of women treated with standard anthracycline-based chemotherapy regimens.
• Risk factors for cardiac toxicity include older age, preexisting cardiac disease, higher cumulative dose of anthracycline, and irradiation of the
• Myelodysplastic syndromes or acute myeloid leukemia canarise as a consequence of chemotherapy. The risk is verylow (0.2 to 1.0 percent) after standard chemotherapy with cyclophosphamide, methotrexate, and fluorouracil or anthracycline-based adjuvant chemotherapy
Burstein HJ, Winer EP
N Engl J Med 343:1086, October 12, 2000
![Page 16: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/16.jpg)
16
More on cardiotoxicitySEER Database
Women aged 66 to 70 years ( but not in 71-80 yr cohort!)Hazard ratio (HR) for CHF due to adjuvant anthracyclines
(compared with other chemotherapy):1.26 (95% CI 1.12-1.42)
AT 10 YEARS: 38% of anthracycline-treated women had CHF vs 33% with non-anthracycline chemotherapy and 29% among those who had had no adjuvant chemotherapy.
Pinder MC, Duan Z, Goodwin JS et al. J Clin Oncol 2007;25:3808-3815
![Page 17: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/17.jpg)
![Page 18: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/18.jpg)
Combination chemotherapy vs capecitabine in ESBC patients > 65 years: improved outcomes
Primary end point: relapse-free survival Results
– 2 toxic deaths with capecitabine– Significant improvement in DFS and OS with CMF/AC
54321
0.8
p=0.019
H.B. Muss et al. ASCO 2008. Abstract 507
Muss HB et al. ASCO 2008; Abstract 507.
![Page 19: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/19.jpg)
19
THE BIOLOGICAL REALITY
Muss et al N ENgl J Med 2008
BUT WHAT ABOUT ER+ PATIENTS WITH HIGH Ki-67 ?
![Page 20: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/20.jpg)
20
NO, I DID NOT FORGET HER-2!
Arnd Hönig earlier today….
![Page 21: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/21.jpg)
T*C vs AC USO 9735Overall survival by treatment and age group
Jones S et al. SABCS 2007. Abstract 12. J Clin Oncol 2009
![Page 22: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/22.jpg)
Hematologic and late cardiac toxicity by treatment and age (USO 9735)
Adverse event
< 65 years ≥ 65 years
TC(N=428)
AC(N=428)
TC(N=78)
AC(N=82)
Anemia <1 1 <1 5
Neutropenia 60 54 52 59
Thrombocytopenia <1 1 0 <1
Febrile neutropenia 4 2 8 4
Grade 3/4 hematologic toxicities (%)
Jones S et al. SABCS 2007. Abstract 12. J Clin Oncol 2009
3 MDS/leukemias and 1 death due to CHF in the AC arm
![Page 23: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/23.jpg)
![Page 24: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/24.jpg)
Breast adjuvant trials for older patients GERMANY: “ICE”
German Cooperative Group. 7th Meeting of the International Society of Geriatric Oncology 2007
No cytotoxic
treatment
![Page 25: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/25.jpg)
25
ICE at ESMO ECCO 091409 pts Median age 71 years (range 64–88)570 (80.7%) HR + and 133 (19.3%) HR -335 (48.2%) LN + and 368 (51.8%) LN -
305 SAEs: gastrointestinal (45), skin (38) and cardiac (43) disorders
T. Reimer et alEuropean Journal of Cancer SupplementsVol 7 No 2, September 2009, Page 215
![Page 26: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/26.jpg)
26
MANY ELDERLY PATIENTS BENEFIT
FROM ADJUVANT CHEMOTHERAPY FOR
BREAST CANCER
but doxorubicin might not be the best choice!
![Page 27: Adjuvant Chemotherapy for Elderly Women with Breast Cancer ... · October 2009. 2. 3 COMORBIDITIES and concomittant treatment modulate strategies for non MBC BACKGROUND MESSAGE. 4](https://reader033.vdocument.in/reader033/viewer/2022060712/60785c869439ce5fab5048e5/html5/thumbnails/27.jpg)
2727
THANK YOUTHANK YOUto all the patientsto all the patients
and their and their physicians, nurses and physicians, nurses and carerscarers